Since 2015, cases of hepatitis E have been reported in the Bentiu camp in South Sudan, Africa, which hosts over 100,000 people displaced from conflict and flooding. The first mass reactive vaccination campaign against hepatitis E using the Hecolin® vaccine, the key findings of the campaign and unanswered questions, are discussed by Dr Iza Ciglenecki (Médecins Sans Frontières, Geneva, Switzerland) in this touchINFECTIOUSDISEASES interview.
The abstract ‘The first mass reactive vaccination campaign against hepatitis E in Bentiu, South Sudan: feasibility, vaccination coverage and two-dose vaccine effectiveness‘ was presented at EASL 2023, 21–24 June 2023, Vienna, Austria.
Questions:
- Could you give us an overview of the mass reactive vaccination campaign against hepatitis E in Bentiu, South Sudan? (0:19)
- What were the key findings, and what are the implications for clinical practice? (2:49)
- What questions remain unanswered and what future studies are planned? (3:46)
Disclosures: Iza Ciglenecki has nothing to disclose in relation to this video interview.
Support: Interview and filming supported by Touch Medical Media Ltd. Interview conducted by Atiya Henry.
Filmed in coverage of EASL 2023
Access further content on hepatitis
